Page last updated: 2024-09-03
pn 202-791 and san 202791
pn 202-791 has been researched along with san 202791 in 1 studies
Compound Research Comparison
| Studies (pn 202-791) | Trials (pn 202-791) | Recent Studies (post-2010) (pn 202-791) | Studies (san 202791) | Trials (san 202791) | Recent Studies (post-2010) (san 202791) |
|---|---|---|---|---|---|
| 44 | 0 | 1 | 31 | 0 | 2 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Kan, E; Kelly, JE; Lokuta, AJ; Nishio, M; Sagawa, K; Sagawa, T; Tsai, J; Wasserstrom, JA | 1 |
Other Studies
1 other study(ies) available for pn 202-791 and san 202791
| Article | Year |
|---|---|
Activation of purified cardiac ryanodine receptors by dihydropyridine agonists.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels, L-Type; Dihydropyridines; Dogs; Membrane Potentials; Myocardium; Nicotinic Acids; Nifedipine; Oxadiazoles; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum; Stereoisomerism | 2001 |